GLENMARK PHARMACEUTICALS LTD. - Glenmarks novel molecule 'GRC 27864' for chronic inflammatory diseases including pain entering human trials

Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 03, 2014 titled "Glenmarks novel molecule GRC 27864 for chronic inflammatory diseases including pain entering human trials".